Systemic Infection – Fungemia
Fungemia is defined as the presence of fungi in the bloodstream, which is normally a sterile environment. As these fungi multiply, a potentially life-threatening infection called sepsis can develop. These conditions arise from fungi originating elsewhere in the body. Our fungemia studies allow for in vivo screening of antimicrobial activity to rapidly identify the most promising therapies.
We have established a fungemia model in mice (validation in rats is available upon request) in which animals receive a challenge with a fungal pathogen via intravenous (IV) injection in the lateral tail vein. Test articles may be administered via oral gavage (PO) or subcutaneous (SC), intravenous (IV), or intraperitoneal (IP) injection. The route, duration, and frequency of dosing can be customized to meet client needs. Endpoints for this study include mortality tracking and CFU burden in harvested organs and/or blood. Pharmacokinetic profiling, blood chemistry, and histology are available upon request.
TransPharm has validated a fungemia model using the following pathogens:
- Aspergillus fumigatus
- ATCC 3073
- Candida albicans
- ATCC SC5314
Additional validations are available upon request.